Core Viewpoint - BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction valued at approximately $4.8 billion, which is expected to enhance BioMarin's revenue growth and diversify its product portfolio in the rare disease market [2][3][4]. Group 1: Acquisition Details - The acquisition will add two marketed high-growth products, Galafold and Pombiliti + Opfolda, which generated combined revenues of $599 million over the past four quarters [1][4]. - The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second quarter of 2026, pending regulatory clearances and stockholder approval [2][3]. - BioMarin intends to finance the acquisition through cash on hand and approximately $3.7 billion of non-convertible debt financing [8]. Group 2: Financial Impact - The acquisition is expected to be accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the first 12 months post-close and substantially accretive beginning in 2027 [1][4][5]. - BioMarin is targeting a gross leverage of less than 2.5x within two years after the close of the transaction, demonstrating a commitment to deleveraging [5][8]. Group 3: Strategic Fit - The combination of BioMarin and Amicus is seen as a strategic fit due to both companies' dedication to transforming care for patients with rare diseases [3][4]. - The acquisition will strengthen BioMarin's commercial portfolio and provide opportunities to expand access to Galafold and Pombiliti + Opfolda across its global footprint [1][4][5]. Group 4: Product Information - Galafold is the first oral treatment for Fabry disease, while Pombiliti + Opfolda is a two-component therapy for Pompe disease, both targeting lysosomal storage disorders [4][15]. - Amicus also holds U.S. rights to DMX-200, an investigational small molecule for treating focal segmental glomerulosclerosis, which is in Phase 3 development [4].

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BioMarin Pharmaceutical has agreed to buy Amicus Therapeutics in a $4.8 billion deal that would hand it two marketed drugs for rare diseases and a third asset in late-stage human testing. The all-cash acquisition, announced Friday, has BioMarin paying $14.50 for each Amicus share, or a 33% premium to the latter’s closing stock price on Thursday. The deal has u ...

Core Insights - The biotech industry has shown strong performance in 2025 despite macroeconomic uncertainties, driven by new drug approvals and pipeline progress [1][2] - Mergers and acquisitions (M&A) have surged in 2025, with large companies expanding their portfolios through strategic collaborations and acquisitions [2][9] - Smaller biotech firms leveraging breakthrough technologies are gaining attention, contributing to overall sector momentum [2] Industry Overview - The Zacks Biomedical and Genetics industry includes biopharmaceutical and biotechnology companies that develop innovative drugs using advanced technologies [4] - The industry has outperformed both the Zacks Medical sector and the S&P 500, with a 22.1% gain over the last six months compared to 12.5% and 16.5% respectively [18] - The current valuation of the industry, based on the trailing 12-month price-to-sales ratio, is 2.47X, lower than the S&P 500's 5.96X and the Zacks Medical sector's 2.66X [19] Trends and Challenges - Key trends shaping the industry include a focus on innovation, the use of AI in drug discovery, and the rise of precision medicine [6][12] - Successful commercialization remains a challenge for smaller biotechs, often leading to collaborations with larger firms for shared sales or royalties [7] - Pipeline setbacks and potential tariffs pose risks, as developing drugs is costly and time-consuming, with many therapies taking years to gain approval [13][14] Notable Companies - Amicus Therapeutics has seen strong performance with its lead drug Galafold, which is approved for Fabry disease, and has settled patent litigation to fend off generic competition [21][22] - ANI Pharmaceuticals has a diversified focus on rare diseases and generics, with a notable 70% year-over-year sales increase for its ACTH-based injection [23][24] - Arcutis Biotherapeutics is focused on treating inflammatory skin diseases, with its lead product Zoryve performing well and expanding its label [25][26] - Tango Therapeutics is developing precision medicine for oncology, with promising data from its ongoing studies [27][28] - Pacira BioSciences is expanding its lead drug Exparel's label and has seen a 36.4% gain in shares over the past year [29][30]

Industry Overview - The biotech industry has shown strong performance in 2025 despite a challenging macroeconomic environment, driven by new drug approvals and pipeline progress [1] - Mergers and acquisitions (M&A) surged in 2025, with large pharmaceutical and biotech companies expanding their portfolios through strategic collaborations and acquisitions [2] - The Zacks Biomedical and Genetics industry has outperformed both the Zacks Medical sector and the S&P 500, gaining 22.1% in the last six months compared to 12.5% and 16.5% respectively [18] Key Trends - Innovation and execution are critical, with a focus on high-profile drugs and innovative pipeline development, particularly with the rise of AI technology in drug discovery [6] - Successful commercialization is essential for drug uptake, often requiring collaborations with larger firms due to funding and expertise limitations of smaller biotechs [7] - Pipeline setbacks and potential tariffs pose challenges, as drug development is costly and time-consuming, with many drugs taking years to gain regulatory approval [13][14] Notable Companies - Amicus Therapeutics (FOLD) has performed well, with its lead drug Galafold showing strong demand and recent FDA approval for Pombiliti + Opfolda boosting its portfolio [24] - ANI Pharmaceuticals (ANIP) has seen significant growth in its rare disease franchise, with sales of its ACTH-based injection Cortrophin Gel surging 70% year-over-year [28] - Arcutis Biotherapeutics (ARQT) is focused on treating inflammatory skin diseases, with its lead product Zoryve performing well and expanding its label [32] - Tango Therapeutics is developing precision medicine for oncology, with promising data from its ongoing studies [36] - Pacira BioSciences (PCRX) maintains momentum with its lead drug Exparel and is looking to expand its label further [38]

Key Takeaways FOLD touched a 52-week high as shares rally 87.6% in six months, beating the industry, sector and S&P 500.Galafold is the key revenue driver, generating $371.5M in the first nine months of 2025, up 12% Y/Y.Pombiliti Opfolda sales reached $77.5M in the first nine months of 2025, reflecting 61.5% y/y growth.Shares of Amicus Therapeutics (FOLD) touched a 52-week high of $11.14 on Dec. 15. The stock is currently trading at $10.88.Shares of Amicus have surged 87.6% in the past six months compared w ...

Company Performance - Amicus Therapeutics, Inc. (NASDAQ:FOLD) reached a new 52-week high of $10.85 during intra-day trading, closing at $10.55, reflecting a 6.57% increase [1] - The company reported a net income of $17.3 million in Q3, a turnaround from a net loss of $6.7 million in the same period last year [4] - Net product sales increased by 20% year-on-year, reaching $169 million, driven by strong sales from Galafold and Pombiliti + Opfolda [4] Sales Breakdown - Galafold sales amounted to $138 million, a 15% increase from $120.38 million in the same quarter last year [5] - Sales for Pombiliti + Opfolda surged by 45%, totaling $30.7 million compared to $21 million in the previous year [5] Analyst Ratings - Zacks Research issued a "strong buy" recommendation for Amicus Therapeutics, with a consensus price target of $15.90, indicating a potential upside of 50.7% from the latest closing price [2] - Analysts have raised EPS targets for the stock, reflecting optimism about the company's ability to report better-than-expected earnings [3]

Amicus Therapeutics (FOLD) closed the last trading session at $9.9, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.9 indicates a 60.6% upside potential.The average comprises 10 short-term price targets ranging from a low of $11.00 to a high of $21.00, with a standard deviation of $3.35. While the lowest estimate indicates an increase of 11.1% from the current pric ...

Core Insights - The Federal Reserve is expected to cut interest rates again, contributing to a strong earnings outlook for 2026, which may encourage investors to add to their portfolios in December and early 2026 [1] Group 1: Investment Opportunities - Investors are encouraged to seek out cheap stocks trading under $10 that have strong Zacks Ranks, indicating improving earnings outlooks [2] - Stocks priced between $5 and $10 are generally considered less risky than penny stocks, making them more appealing to investors [5] - A screening process is outlined to identify potential winning stocks under $10, focusing on Zacks Rank, broker ratings, analyst coverage, earnings estimate revisions, price, and trading volume [6][8] Group 2: Specific Stock Highlight - Amicus Therapeutics (FOLD) is highlighted as a promising biotech stock, with a focus on developing medicines for rare diseases [9] - The company reported a 17% revenue growth in Q3 and achieved GAAP profitability, with projections of 19% revenue growth in 2025 and 2026, reaching $745.4 million [10] - FOLD is expected to expand its adjusted earnings by 50% in FY25 and 87% in FY26, with a current Zacks Rank of 1 (Strong Buy) [11]

Core Viewpoint - Amicus Therapeutics (FOLD) is positioned as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating a positive earnings outlook that may continue to drive stock performance [1][9]. Earnings Estimate Revisions - Analysts have shown growing optimism regarding Amicus Therapeutics' earnings prospects, reflected in the upward trend of earnings estimate revisions, which historically correlate with stock price movements [2]. - For the current quarter, the earnings estimate is projected at $0.14 per share, representing a 55.6% increase from the previous year, with a 10.71% rise in consensus estimates over the last 30 days [5]. - The full-year earnings estimate stands at $0.36 per share, marking a 50.0% increase from the prior year, with a notable 77.78% increase in consensus estimates due to two upward revisions and no negative changes [6][7]. Zacks Rank and Performance - Amicus Therapeutics has achieved a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts on the positive earnings revisions, which historically lead to outperformance in stock returns [3][8]. - Stocks rated Zacks Rank 1 and 2 have shown significant outperformance compared to the S&P 500, suggesting a favorable investment environment for Amicus Therapeutics [8]. Recent Stock Performance - The stock has gained 11.8% over the past four weeks, driven by solid estimate revisions, reinforcing the potential for further price appreciation as earnings growth prospects improve [9].

Key Takeaways FOLD's Galafold delivered $371.5M in the first nine months of 2025, up 12% year over year.Patent settlement with Teva blocks Galafold generics in the United States until January 2037.FOLD's Pombiliti Opfolda earned $77.5M in nine-month 2025 sales, rising 61.5% year over year.Amicus Therapeutics (FOLD) has been making meaningful progress with its lead product, Galafold (migalastat), which has been driving the majority of the company’s revenues. The drug has remained a key top-line driver for Am ...